CQ80
CQ80 is a PEPD/XPNPEP1 inhibitor and selective CARD8 inflammasome activator. CQ80 has IC50 values of 0.91 μM for PEPD, 43 μM for XPNPEP1. CQ80 promotes the accumulation of Xaa-Pro peptides by inhibiting PEPD and XPNPEP1, releases the fragment of CARD8 for inflammasome formation, and induces pyroptosis via GSDMD cleavage. CQ80 can be used for research on inflammasome, CARD8-expressing cancer cells, HIV-1-infected cell clearance, acute myeloid leukemia (AML).
For research use only. We do not sell to patients.
- CAS No.: 3034207-17-2
- Formula: C19H35N3O5
- Molecular Weight:385.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MV4-11 | IC50 |
0.27 μM
Compound: CQ80; 14p
|
Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 24 hrs by celltiter-glo assay
Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 24 hrs by celltiter-glo assay
|
[PMID: 36724486] |
In Vitro
CQ80 (0.15 nM-100 μM; 24 h) induces CASP1-dependent pyroptosis in MV4-11 cells with an IC50 of 0.27 μM, and shows potent cytotoxicity against OCI-AML2 cells[1].
CQ80 (6.25 μM; 6 h) promotes Propidium Iodide (PI) (HY-D0815) uptake in MV4-11 and OCI-AML2 cells, indicating lytic cell death[1].
CQ80 (20 μM; 24 h) induces lactate dehydrogenase (LDH) release and gasdermin D (GSDMD) cleavage in MV4-11, OCI-AML2, THP-1 cells and human resting T cells[1].
CQ80 (20 μM; 24 h) shows no activity in N/TERT-1 keratinocytes, mouse bone marrow-derived macrophages (BMDMs) and RAW264.7 cells, failing to activate NLRP1 inflammasome[1].
CQ80 (20 μM; 24 h) does not induce additional pyroptosis in DPP8/9 knockout THP-1 cells, and PEPD/XPNPEP1 double knockout THP-1 cells are completely resistant to CQ80[1].
CQ80 (20 μM; 6 h) disrupts the CARD8-DPP9 ternary complex in HEK293T cells stably expressing CASP1 and GSDMD[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MV4-11 WT cells, MV4-11 CASP1⁻/⁻ cells, OCI-AML2 cells
-
Concentration:100 μM to 15.2 nM (three-fold dilutions)
-
Incubation Time:24 h
-
Result:Induced CASP1-dependent cell death in MV4-11 WT cells, with no such effect in MV4-11 CASP1⁻/⁻ cells.
Exhibited higher cytotoxicity against OCI-AML2 cells compared to CQ31.
-
Cell Line:THP-1 cells, THP-1 PEPD/XPNPEP1⁻/⁻ cells, MV4-11 cells, OCI-AML2 cells, human resting T cells
-
Concentration:20 μM
-
Incubation Time:24 h
-
Result:Detected GSDMD cleavage bands, while no such bands were found in THP-1 PEPD/XPNPEP1⁻/⁻ cells
-
Cell Line:HEK293T CASP1+GSDMD cells
-
Concentration:20 μM
-
Incubation Time:6 h
-
Result:GSDMD cleavage bands were detected in HEK293T cells after combined treatment with dTAG-13
Chemical Information
-
CAS No. 3034207-17-2
-
Molecular Weight 385.50
-
Formula C19H35N3O5
-
SMILES
CC(C[C@H](NC([C@@H]1CCCN1C([C@H]([C@@H](CC(C)C)N)O)=O)=O)C(OC)=O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- CQ80
- 3034207-17-2
- CQ 80
- CQ-80
- Pyroptosis
- PEPD/XPNPEP1 inhibitor
- selective CARD8 inflammasome activator
- induces pyroptosis
- MV4-11 cells
- OCI-AML2 cells
- THP-1 cells
- HEK 293T cells
- RAW264.7 cells
- human resting T cells
- mouse bone marrow-derived macrophages (BMDMs)
- acute myeloid leukemia (AML)
- HIV-1 infection
- inflammasome
- Inhibitor
- inhibitor
- inhibit